Skip to main content

NICE IDs

16/04/2020
ID1484: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
16/04/2020
ID1547: Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma
16/04/2020
ID1508: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
16/04/2020
ID1414: Esketamine for treatment-resistant depression
16/04/2020
ID1140: Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck
16/04/2020
ID1467: Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies
16/04/2020
ID1516: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
16/04/2020
ID1602: Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy
16/04/2020
ID1499: Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
05/03/2020
ID885: Short bowel syndrome - teduglutide

In development [GID-TA10048] Expected publication date: TBC

26/02/2020
ID927: Afamelanotide for treating erythropoietic protoporphyria

Afamelanotide for treating erythropoietic protoporphyria

02/09/2019
ID1379: Idelalisib for treating follicular lymphoma refractory to 2 treatments

Idelalisib for treating follicular lymphoma refractory to 2 treatments

28/08/2019
ID1397: Rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease

Rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease

Follow AWTTC: